📰 Clinical Trial Program News
Page 6 - Clinical Trial Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Trial Program. Real-time updates on events, politics, business and more.
May 24, 2022
/PRNewswire/ -- In Eli Lilly and Companys (NYSE:LLY) pivotal, Phase 3 LUCENT-2 study, patients with ulcerative colitis (UC) who responded to mirikizumab at 12...
April 4, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
April 4, 2022
– If approved, Actemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalized patients – – Since the begin
February 26, 2022
Press release content from PR Newswire. The AP news staff was not involved in its creation.
February 26, 2022
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed...
February 26, 2022
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed...
February 18, 2022
/PRNewswire/ -- Patients with moderately-to-severely active ulcerative colitis (UC) who took mirikizumab achieved statistically superior rates of clinical...
February 18, 2022
INDIANAPOLIS, Feb. 18, 2022 /PRNewswire/ -- Patients with moderately-to-severely active ulcerative colitis (UC) who took mirikizumab achieved stat...
January 16, 2022
/PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the U.S....
December 17, 2021
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZenecas Tezspire™...